Abstract
A simple, precised and accurate RP-UPLC method has been developed and validated for the simultaneous assay of Telmisartan and Cilnidipine in tablets. Isocratic RP-UPLC method was developed on LC system of Waters Acquity UPLC with PDA detector onWater Acquity BEH C18, 2.1 x 100mm, 1.7μm column as stationary phase with binary gradient mode by using mobile phase as ACN: 0.01M sodium phosphates monobasic dehydrate buffer pH 3.0 with phosphoric acid (68:32, v/v), at a flow rate of 0.5 ml/min and the detection was carried out at 245 nm. Forced degradation study was carried out by oxidation, hydrolysis, photolysis and heating the drug. The method was validated for specificity, linearity, precision, accuracy, robustness and solution stability. The method was found to be linear in the concentration range of 40-160 µg/ml with correlation coefficients of 0.9996 for Telmisartan and 10-40 µg/ml with correlation coefficients of 0.9995 for Cilnidipine. Degradation products produced as a result of stress studies did not interfere with the detection of Telmisartan and Cilnidipine: therefore, the assay can be considered to be stability-indicating.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
